The Doshisha
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
1
Ending by 2030
Jan 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 13 to 22, 2027 · next Feb 13
- 2 fees due Apr 3, 2027
- 1 fee due May 19, 2027The maintenance fee for Liquid-crystal varifocal lens and focal length control method (US 10,481,429) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Composition or method including (t)ew-7197 for treating or preventing corneal endothelial diseases (US 11,857,544) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 2 fees due Sep 5 to 26, 2027 · next Sep 5
Recent changes
- 1 of the patents on this record was granted since Aug 24, 2026
- Nov 10 US 12,788,747 Therapeutic Drug for Diseases Related to Endoplasmic Reticulum Cell Death in Corneal Endothelium
- 2 terms have ended since Aug 24, 2026
- Sep 20 US 11,446,263 CASPASE INHIBITOR-CONTAINING DRUG FOR TREATING OR PREVENTING DISORDERS CAUSED BY TGF-ß, AND APPLICATIONS THEREOm · lapsed on the fee record
- Sep 6 US 11,433,090 Mtor-Inhibitor-Containing Medicine for Treating or Preventing Ophthalmic Symptoms, Disorders, or Diseases, and Application Thereof · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,696,580 | Arteriosclerosis Evaluating Apparatus In force · High confidence | In force | High confidence | |
| US 8,951,401 | Method for Electrochemically Depositing Carbon Film on a Substrate In force · High confidence | In force | High confidence | |
| US 9,555,028 | Drug for preventing/treating ocular disease In force · USPTO record | In force | USPTO record | |
| US 11,730,722 | Corneal Endothelium Ecm Therapeutic Medicaments In force · High confidence | In force | High confidence | |
| US 10,174,284 | Medium, for Culturing Corneal Endothelial Cells, Containing Conditioned Medium from Mesenchymal Stem Cells In force · High confidence | In force | High confidence | |
| US 11,382,904 | Therapeutic Drug for Diseases Related to Endoplasmic Reticulum Cell Death in Corneal Endothelium In force · High confidence | In force | High confidence | |
| US 12,788,747 | Therapeutic Drug for Diseases Related to Endoplasmic Reticulum Cell Death in Corneal Endothelium In force · High confidence | In force | High confidence | |
| US 10,813,920 | Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage In force · USPTO record | In force | USPTO record | |
| US 11,918,630 | Treatment of Retina and Nerve Using Laminin In force · High confidence | In force | High confidence | |
| US 11,633,477 | Novel Treatment of Cornea Using Laminin In force · High confidence | In force | High confidence |
Also on record, not counted in the 35: 4 patents in force now held by others · 51 lapsed for an unpaid fee · 1 ended at full term · 1 past the fee grace period. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
10 pending · 11 abandoned · 27 no status recorded
Rows 11 to 48 of 48 are for members. The first 10 are on the company page.
Pro members see all 48 published applications.